Use of biomarkers in clinical trials and future developments that will help identify novel biomarkers

This publication has 18 references indexed in Scilit:

• Randomized, double-blind, placebo-controlled trial of rapamycin in amyotrophic lateral sclerosis
  Nature Communications, 2023
• SYF2 suppression mitigates neurodegeneration in models of diverse forms of ALS
  Cell Stem Cell, 2023
• Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
  New England Journal of Medicine, 2022
• Repeated neurofilament light chain measurements did not capture Riluzole therapeutic effect in amyotrophic lateral sclerosis patients
  CNS Neuroscience & Therapeutics, 2022
• Mild motor impairment as prodromal state in amyotrophic lateral sclerosis: a new diagnostic entity
  Brain, 2022
• TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion of UNC13A
  Nature, 2022
• Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis
  Nature Neuroscience, 2021
• Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
  New England Journal of Medicine, 2020
• Neurofilament light: A candidate biomarker of presymptomatic amyotrophic lateral sclerosis and phenoconversion
  Annals of Neurology, 2018
• Regulatory T‐lymphocytes mediate amyotrophic lateral sclerosis progression and survival
  EMBO Molecular Medicine, 2012